Skip to main content
Download PDF

Cardioprotective effect of nicorandil on isoproterenol induced cardiomyopathy in the Mdx mouse model

BMC Cardiovascular Disorders volume 21, Article number: 302 (2021) Cite this article

Abstract

Background

Duchenne muscular dystrophy (DMD) associated cardiomyopathy is a major cause of morbidity and mortality. In an in vitro DMD cardiomyocyte model, nicorandil reversed stress-induced cell injury through multiple pathways implicated in DMD. We aimed to test the efficacy of nicorandil on the progression of cardiomyopathy in mdx mice following a 10-day treatment protocol.

Methods

A subset of mdx mice was subjected to low-dose isoproterenol injections over 5 days to induce a cardiac phenotype and treated with vehicle or nicorandil for 10 days. Baseline and day 10 echocardiograms were obtained to assess cardiac function. At 10 days, cardiac tissue was harvested for further analysis, which included histologic analysis and assessment of oxidative stress. Paired student’s t test was used for in group comparison, and ANOVA was used for multiple group comparisons.

Results

Compared to vehicle treated mice, isoproterenol decreased ejection fraction and fractional shortening on echocardiogram. Nicorandil prevented isoproterenol induced cardiac dysfunction. Isoproterenol increased cardiac fibrosis, which nicorandil prevented. Isoproterenol increased gene expression of NADPH oxidase, which decreased to baseline with nicorandil treatment. Superoxide dismutase 2 protein expression increased in those treated with nicorandil, and xanthine oxidase activity decreased in mice treated with nicorandil during isoproterenol stress compared to all other groups.

Conclusions

In conclusion, nicorandil is cardioprotective in mdx mice and warrants continued investigation as a therapy for DMD associated cardiomyopathy.

Peer Review reports

Introduction

Duchenne muscular dystrophy (DMD) is an X-linked recessive genetic disorder which affects 1:3500–5000 males [1, 2]. DMD is caused by mutations in the dystrophin gene that lead to either complete absence of dystrophin or the expression of a significantly truncated and non-functional protein. Dystrophin, as part of the dystrophin glycoprotein complex, serves important roles in both cell membrane stabilization and cell signaling [3, 4]. Clinically, DMD manifests as progressive loss of muscle function, starting with skeletal muscle weakness with progression to wheelchair dependence beginning in the first decade of life. DMD associated cardiomyopathy becomes more evident starting in the second decade of life. With advances in medical management, including mechanical ventilation, DMD patients are living longer and the cardiomyopathy associated with DMD is becoming a significant cause of morbidity and mortality [5,6,7]. The mainstay of current medical management of DMD associated cardiomyopathy is the use of generic heart failure medications, including ACE inhibitors and beta blocker therapy [8]. While these strategies afford some cardiac benefit, they do not take into account the specific molecular mechanisms involved in the development of DMD associated cardiomyopathy.

Multiple cellular and metabolic processes have been implicated in the development of DMD associated cardiomyopathy. Contractile properties are abnormal in DMD affected myocardium [9]. Excessive calcium influx into cardiac myocytes has been implicated in cardiac myocyte dysfunction [10, 11]. Additional molecular mechanisms include impaired nitric oxide production, nitric oxide-cyclic GMP pathway dysregulation, increased reactive oxygen species production, and mitochondrial dysfunction [12,13,14]. Myocardial KATP channels, which have inherent function in sensing the metabolic state of the cell, have gained attention in recent years as appropriate channel function has been found to have cardioprotective properties during times of metabolic stress [15]. KATP channels co-localize with dystrophin, and lack of dystrophin leads to inability of KATP channels to sense intracellular changes in ATP levels [16]. These multiple pathways ultimately culminate to lead to cellular necrosis and fibrosis, which progresses to a clinical phenotype of a dilated cardiomyopathy[17, 18].

Nicorandil is a compound of particular interest as a potential targeted therapy for DMD associated cardiomyopathy, as it modulates several of the metabolic pathways previously shown to be involved in disease development. Nicorandil is a compound with nitrate-like qualities, which acts as a nitric oxide donor, KATP channel opener, and has anti-oxidant properties [19,20,21]. Nicorandil has an established pharmacologic safety profile as it is currently in clinical use as an anti-anginal agent and has been shown to be cardioprotective in other forms cardiomyopathy. Cardioprotective effects have been demonstrated in doxorubicin induced cardiomyopathy in both an in vitro cell model and an in vivo rat model [22, 23]. Nicorandil is most well-studied in ischemia–reperfusion injury following acute coronary events. Several animal models, including canine, rabbit, and rat models have demonstrated that pretreatment with nicorandil leads to decreased infarction size in coronary ischemia–reperfusion injury [24,25,26]. This has translated to clinical benefit in patients, with recent meta-analyses demonstrating benefit of nicorandil administration prior to percutaneous coronary intervention for patients with acute myocardial infarction undergoing primary intervention and patients with coronary artery disease and angina undergoing elective intervention. In both of these groups nicorandil improves ejection fraction and decreases risk of adverse cardiovascular events [27, 28].

For these reasons, it is advantageous to further investigate nicorandil for the treatment of DMD associated cardiomyopathy as it can be quickly translated into a feasible treatment option for these patients. Our lab was the first to study nicorandil in an in vitro DMD model by studying its effect in dystrophin-deficient induced pluripotent stem cell (iPSC) derived cardiomyocytes from DMD patients. Our study demonstrated that in the presence of a cellular stressor, nicorandil was protective against cardiomyocyte injury by decreasing cell injury and cell death through mechanisms that involved preventing the stress-induced increase in reactive oxygen species and loss of the mitochondrial membrane potential [29]. Additionally, we previously showed protective benefits of nicorandil in isolated perfused mdx hearts subject to global ischemia and recovery [29]. The purpose of this study is to extend the investigation of nicorandil to determine whether it would maintain cardioprotective effects in the mdx mouse heart in vivo.

Methods

Animals

C57BL/10ScSn-Dmdmdx/J (mdx) mice were purchased from the Jackson Laboratory (Bar Harbor, Maine) at 8–10 weeks of age then acclimated until the desired age to undergo the subsequently described experimental protocol. A total of 48 female mice (10–14/group) were used for this study. Female mice were used in our study based on prior research demonstrating a more robust cardiac phenotype in mdx females compared to males [30]. Animal group size was determined empirically, with the aim to minimize animal numbers during this early-stage in vivo study. Animals were randomized per cage, with all in the same cage receiving the same treatment. Investigators were not blinded to treatment group allocation. Housing and procedure rooms were under specific pathogen-free conditions. The mice had a 12-h day/night cycle, with daytime being from 7 am to 7 pm. Mice were fed a standard diet of Purina irradiated 5LOD. All animals in this study received humane care in compliance with the “Guide for the Care and Use of Laboratory Animals” published by the US National Institutes of Health (NIH Publication No. 85-23, revised 1996). All animal experiments were performed at the Medical College of Wisconsin and were approved by the institutional animal care and use committee (procedure protocol AUA00003547). This study involved no human subject research.

Study protocol

A short-term subacute injury model using low-dose isoproterenol (Sigma, St. Louis, Missouri) was utilized to induce a cardiac phenotype in 11–14-week mice. The isoproterenol (3 mg/kg) was administered intraperitoneally once daily in the early afternoon for the first 5 days of the ten-day treatment protocol. This dose was chosen empirically with the goal to induce mild cardiac injury, while avoiding mortality. Isoproterenol injury is a well-described means of inducing cardiac injury in mdx mice by means of increased oxidative stress, and sarcolemmal damage [31]. Dosing, mode of isoproterenol delivery, and mortality vary considerably between studies using an isoproterenol induced cardiac phenotype [32, 33]. While beta receptor agonism with isoproterenol has been shown to lead to cardiac hypertrophy in normal myocardium, this would not be expected with beta agonism in dystrophin deficient myocardium given its well-described phenotype of a dilated cardiomyopathy without pathologic cardiac hypertrophy [34,35,36]. Nicorandil (Selleckchem, Houston, Texas) was given via drinking water at 6 mg/kg/day for the duration of the ten-day treatment protocol [37, 38]. The vehicle was ddH20, which was administered in the drinking water in the same period as nicorandil. It is not expected to have any effects. The animals were assigned to 4 groups: vehicle (n = 10), nicorandil treatment (n = 10), isoproterenol treatment (n = 14), and isoproterenol plus nicorandil treatment (n = 14). At the ten-day timepoint, the hearts were harvested, and blood was collected for further analysis. Study protocol is outlined in Fig. 1.

Fig. 1
figure 1

Schematic of the 10 day treatment protocol

Full size image

Echocardiography and image analysis

Transthoracic echocardiograms were performed in anesthetized (2.5% isoflurane) mice at baseline and at 10 days. Focused 2-dimensional echocardiogram with Doppler was performed using a commercially available echocardiographic system (Vivid 7, General Electric) with an 11 MHz M12-L linear array transducer. An M-mode image was taken in the cardiac short axis at the level of the papillary muscles. From this image the following measurements were obtained: ejection fraction % (EF), fractional shortening % (FS), left ventricular end diastolic volume (LVEDV), and left ventricular end systolic volume (LVESV). An average of three consecutive cardiac cycles was used for each measurement.

Histology

The heart was dissected and fixed in 4% paraformaldehyde overnight at 4 °C. The tissues were then washed with PBS and embedded using sucrose and OCT. Frozen hearts were sectioned onto slides in 8 micron thick axial sections. Slides were stained with Masson’s Trichrome stain and hematoxylin counterstain (Masson Trichrome Special Stain Kit, Leica, Buffalo Grove, Illinois). Images of the entire section were obtained (Nikon Super Coolscan 9000). Metamorph image analysis software was used to quantify percent fibrosis by means of thresholding the specific blue coloration of collagen positive regions. The thresholded area was compared to total area of cardiac tissue and represented as percentage of total tissue area. An average of two sections for each sample was used for each measurement.

Protein extraction and western blot

Protein extraction and immunoblot analysis was performed on individual mouse heart protein isolates as previously described (n = 2 per group) [39]. Proteins were isolated by homogenization with a Dounce homogenizer in RIPA buffer (Sigma, St. Louis, Missouri) and Halt protease/phosphatase inhibitor (ThermoFisher, Waltham, Massachusetts) and centrifuged at 11,000g at 4 °C for 10 min. Protein concentration was measured by commercially available bicinchoninic acid assay kit (Thermo Scientific, Waltham, Massachusetts). Fifteen micrograms of protein per sample was separated on a 4–20% Criterion TGX Stain-Free Protein Gel (BioRad, Hercules, California) and transferred onto a polyvinylidene difluoride membrane. After the membrane was blocked with SuperBlock T20 (TBS) Blocking Buffer (ThermoFisher, Waltham, Massachusetts) with 0.1% Tween-20, the membrane was incubated with primary antibody Anti-NADPH oxidase 4, 1:300 dilution (ab133303, Abcam, Cambridge, MA), Anti-SIRT3, 1:1,000 dilution (ab264041, Abcam, Cambridge, MA), Anti-TNF alpha, 1:1,000 dilution (ab6671, Abcam, Cambridge, MA), Anti-NF-kB p65, 1:2,000 dilution (ab16502, Abcam, Cambridge, MA), anti-SOD2/MnSOD, 1:5,000 (ab13533, Abcam, Cambridge, MA) and Vinculin (E1E9V) XP Rabbit mAb (HRP Conjugate), 1:5,000 dilution (18799, Cell Signaling, Danvers, MA) for 2 h at room temperature. After washing, the blots were incubated with a secondary antibody at a 1:10,000 dilution (donkey anti-rabbit peroxidase conjugated, 711-035-152, Jackson ImmunoResearch, West Grove, PA) for 1 h at room temperature followed by chemiluminescence solution (Amersham ECL Prime, RPN2236, Cytiva, Marlborough, MA) prior to imaging on a ChemiDoc imaging system (BioRad, Hercules, California). Protein quantification was performed using BioRad ImageLab software and compared to the vinculin loading control.

Xanthine oxidase activity

Xanthine oxidase activity was determined in mouse serum (n = 4 per group) using a commercially available fluorometric assay kit (Cayman Chemical, Ann Arbor, Michigan).

Reverse transcriptase PCR

RNA isolation was performed according to previously described protocol [29]. The forward and reverse primer sequences of following primers were used: superoxide dismutase 2 (SOD2) exon 3 to 4 (forward 5′-TCAATGGTGGGGGACATATT-3′, reverse 5′-GAACCTTGGACTCCCACAGA-3′), sirtuin 3 exon 4–5 (forward 5′-ACTTCCTGAGGCTCCTCCAC-3′, reverse 5′- ACAGACCGTGCATGTAGCTG-3′), NADPH oxidase (NOX)-2 (forward 5′-TCGAAAACTCCTTGGGTCAG-3′, reverse 5′-AGCATTTGGTGTGATGGTCA-3′), NOX-4 (forward 5′-AGCATCTGCATCTGTCCTGA-3′, reverse 5-CATGTGATGTGTAGAGTCTTGC-3′). Mouse GAPDH was used as a normalization control. Experiments were performed with an n = 6 per group, with the exception of the vehicle treated group given limited tissue availability.

Statistical analysis

Statistical analyses were performed using GraphPad Prism 9 software (Version 9.1.0). Data are displayed as mean ± standard error of the mean. Paired student’s t test was used for in group comparisons between baseline and day 10 echocardiographic parameters. For the remainder of experimental assays, one-way ANOVA with Tukey’s multiple comparisons test post-hoc analysis was used for multiple group comparisons. P values of less than 0.05 were considered significant.

Results

Nicorandil is protective against isoproterenol-induced cardiac injury

Previously, our lab demonstrated that treatment with nicorandil conferred protective effects in iPSC derived cardiomyocytes from DMD patients by means of decreasing cell injury and death, maintenance of the mitochondrial membrane potential, and decreasing reactive oxygen species production [29]. To assess the effect of nicorandil in vivo, noninvasive functional cardiac assessment was performed via transthoracic echocardiograms both at baseline and after a 10 day treatment protocol in 11–14 week old mdx mice. As part of this treatment protocol, a subset was treated with once daily intraperitoneal injections of isoproterenol for 5 days to induce a mild cardiac phenotype. We intentionally aimed for a mild cardiac injury so as to not induce death in treated mice in order to maintain the ability for in vivo functional cardiac assessment. Additionally, we felt that a mild cardiac injury in our induced cardiac phenotype was more analogous to disease progression of DMD associated cardiomyopathy in humans, which presents as gradual decline in cardiac function rather than an acute, severe decline in function. Comparisons were made between baseline and day 10 measurements within each group. Baseline measurements of ejection fraction (EF), fractional shortening (FS), left ventricular end systolic volume (LVESV), left ventricular end diastolic volume (LVEDV), and stroke volume (SV) were comparable between groups. Isoproterenol induced a mild cardiac injury with a small, but statistically significant decrease in cardiac function as indicated by a decreased EF and FS and an increased LVESV. Concomitant treatment with nicorandil prevented isoproterenol-induced cardiac injury (Table 1). Additionally, isoproterenol induced a cardiac phenotype of a dilated cardiomyopathy in isoproterenol treated animals, with increased LVEDV and increased stroke volume, which is consisted with the dilated cardiomyopathy phenotype in DMD patients. Nicorandil prevented left ventricular dilation (Table 1). Heart rate was uniformly higher in the day 10 measurements, statistically significantly so in the isoproterenol treated group. This likely was more representative of level of sedation given the presence of higher heart rate at day 10 measurement in all groups, though this may have been more significant in the isoproterenol treated group due to the development of the induced cardiomyopathy.

Table 1 Demographic characteristics and echocardiographic data
Full size table

Nicorandil is protective against isoproterenol-induced cardiac fibrosis

Frozen cardiac tissue sections were evaluated for collagen deposition, which is representative of myocardial fibrosis. Tissue sections from all study mice were stained with Masson’s trichrome stain, which enables one to distinguish blue stained collagen fibers from red stained muscle fibers. As shown in Fig. 2, vehicle and nicorandil-only treated hearts have minimal fibrosis with 0.6–0.7% of total cardiac tissue area consisting of collagen. Isoproterenol induced a significant degree of fibrosis compared to baseline with a nearly three-fold increase in collagen staining at 1.8 ± 0.4% of total cardiac tissue area consisting of collagen. Concomitant treatment with nicorandil prevented the development of cardiac fibrosis, with those mice receiving both nicorandil and isoproterenol injury protocol having comparable percentage fibrosis compared to vehicle treated animals.

Fig. 2
figure 2

Histologic assessment of myocardial fibrosis. Frozen mouse heart tissue was sectioned and stained with Masson’s trichrome stain to assess myocardial fibrosis (blue tissue coloration). a Representative images of Masson’s trichrome stained heart tissue, with groups identified as follows: 1: Vehicle, 2: Nicorandil, 3: Isoproterenol, 4: Isoproterenol + Nicorandil. Images are centered in the interventricular septum (IVS) and areas corresponding to right ventricle (RV) and left ventricle (LV) are labeled. b Quantification of percent fibrosis on Masson’s trichrome staining, represented as percentage of total tissue area ± SEM. Isoproterenol led to an increase in percent fibrosis. Nicorandil was protective against isoproterenol-induced fibrosis. Number of samples for each experimental group: vehicle n = 10, Nicorandil n = 10, Isoproterenol n = 14, Isoproterenol + Nicorandil n = 14. SEM, standard error of the mean. (*p < 0.05 vs vehicle)

Full size image

Nicorandil modulates reactive oxygen species formation

It is well-established that increased reactive oxygen species (ROS) production plays a role in many cardiac diseases, including in the development of DMD associated cardiomyopathy. Quantitative RT-PCR was performed to assess gene expression of several genes known to be involved in ROS production. Of note, for our RT-PCR experiments, Nicorandil-only treated mdx mice were used as a control due to tissue availability. This group was designed to act as a functional secondary control since mice of this age would not be expected to naturally exhibit a cardiac phenotype without employing means to induce cardiac involvement. NADPH oxidase (NOX) is an enzyme which functions in the creation of superoxide free radicals. There are several NOX isoforms, with the two most expressed in cardiac tissue being isoforms NOX-2 and NOX-4 [40]. We found that expression of NOX-4 was significantly increased with isoproterenol compared to nicorandil only treated animals. There was a similar, though not statistically significant, increase in NOX-2 gene expression with isoproterenol. Treatment with nicorandil prevented increased NOX-2 and NOX-4 expression while undergoing isoproterenol stress (Fig. 3). NOX-4 protein expression did not differ significantly between groups (Fig. 4).

Fig. 3
figure 3

Reactive oxygen species gene expression. Quantitative RT-PCR was performed on mouse cardiac tissue to quantify mRNA expression of select genes involved in reactive oxygen species formation, including NOX2, NOX4, SOD2, and Sirtuin 3. Expression of NADPH Oxidase (NOX) 4 and NOX 2 were increased with isoproterenol stress. Treatment with nicorandil prevented this change in gene expression. (n = 6, *p ≤ 0.05, **p ≤ 0.01, and ***p ≤ 0.001)

Full size image
Fig. 4
figure 4

Reactive oxygen species protein expression. Western blot was performed on mouse cardiac tissue to assess protein expression of selected proteins involved in reactive oxygen species production and inflammation. Relative protein expression is shown in part a, and cropped representative immunoblot images are shown in part b. the vinculin loading control is shown for each separate western blot that is shown in the figure. Note that NFkB and TNFα were assessed using different regions of the same western blot membrane. Full-length blots are presented in Additional files 1, 2, 3, 4: Figs. 1–4 (n = 2, *p ≤ 0.05, **p ≤ 0.01)

Full size image

Nicorandil decreases mitochondrial ROS levels by increasing antioxidant gene expression, such as SOD2 and sirtuin 3 [41,42,43]. In our previous in vitro studies, we showed that nicorandil increased SOD2 gene expression after stress which was associated with a decrease in mitochondrial ROS levels as well [29]. Examining the myocardium from each group did not reveal a significant change in SOD2 or sirtuin 3 gene expression (Fig. 3). However, SOD2 protein expression increased significantly with nicorandil treatment, irrespective of concomitant isoproterenol stress (Fig. 4). Sirtuin 3 protein expression did not differ between groups (Fig. 4).

Previous studies have demonstrated that the inflammatory markers, nuclear factor kappa beta (NF-kB) and tumor necrosis factor alpha (TNF-α) are increased in mdx myocardium[44]. To evaluate the impact of nicorandil on inflammation, protein expression of NFkB and TNF-α was evaluated. There was no difference in NF-kB protein expression between groups. TNF-α protein expression was increased in those treated with concurrent isoproterenol and nicorandil compared to both vehicle and isoproterenol treated animals (Fig. 4). Notably, there was no inflammatory cell infiltrate seen in the histologic sections from any group (Fig. 2).

Nicorandil has also been shown to decrease ROS by inhibiting xanthine oxidase activity [45]. Furthermore, xanthine oxidative inhibitors decreased ROS levels in DMD-iPSC derived cardiomyocytes suggesting that xanthine oxidase contributes to the oxidative stress in DMD associated cardiomyopathy [29]. Therefore, we evaluated whether nicorandil was able to alter xanthine oxidase activity using a commercially available fluorometric assay kit. Xanthine oxidase activity was significantly decreased in those mdx mice treated with nicorandil while undergoing isoproterenol stress compared to all other treatment groups (Fig. 5).

Fig. 5
figure 5

Xanthine oxidase activity: Xanthine oxidase activity was assessed in cardiac tissue by fluorometric assay kit (Cayman Chemical). Nicorandil led to a decrease in xanthine oxidase activity with concomitant isoproterenol treatment protocol (n = 4, *p < 0.05 vs vehicle)

Full size image

Discussion

This study provides the first evidence that nicorandil exerts cardioprotective effects against DMD associated cardiomyopathy in mdx mice in vivo. We demonstrated that nicorandil prevents isoproterenol induced left ventricular dilation, cardiac dysfunction and cardiac fibrosis. An important measure by which prior investigators have demonstrated the cardioprotective effect afforded by nicorandil in other disease states is by means of decreased ROS production. Nicorandil has been found to decrease ROS produced from NADPH oxidase and xanthine oxidase and to increase anti-oxidants such as SOD2, glutathione peroxidase, and catalase [21,22,23, 29]. Our study further supported the ROS modulating effect of nicorandil. Nicorandil mitigated isoproterenol-induced increase in NADPH oxidase gene expression, increased SOD2 protein expression, and decreased xanthine oxidase activity. Our lab previously demonstrated in an in vitro DMD model that nicorandil was protective against cardiomyocyte injury and showed protective benefits in the isolated perfused mdx heart [29]. This study expands on that work and gives supportive evidence to warrant continued investigation of nicorandil as a treatment of DMD associated cardiomyopathy.

The current standard of care for management of DMD associated cardiomyopathy includes the use of generic heart failure therapies with ACE inhibitors, angiotensin receptor blockers, and beta blocker therapies based on few small, clinical studies demonstrating clinical benefit on left ventricular function and survival [46,47,48,49]. There is, however, a notable lack of therapies directed toward the specific cellular mechanisms that lead to DMD associated cardiomyopathy. Significant attention in recent years has been paid to gene targeted therapies, which are in varying stages of development [50]. These technologies may also be mutation-specific and may have differential effectiveness in cardiac versus skeletal muscle, which could limit the timely and broad applicability. Nicorandil is of particular interest as a targeted therapeutic given that its multiple mechanisms of action as a nitric oxide donor, anti-oxidant, and KATP channel opener allow it to act on many of the molecular processes involved in the development of DMD associated cardiomyopathy [19,20,21]. Compounds that target just one of these molecular pathways have been investigated without significant success in translating to broad clinical applicability. For instance, to combat the abnormal nitric oxide-cyclic GMP signaling in DMD associated cardiomyopathy, phosphodiesterase (PDE) 5 inhibitors have been explored [51]. Sildenafil prevented the diastolic dysfunction seen echocardiographically in 15 month old mdx mice. Further, when started after the onset of cardiac dysfunction, sildenafil reversed these findings of cardiomyopathy. These encouraging findings were unfortunately not translated into clinical benefit with no improvement in cardiac magnetic imaging derived indices of cardiomyopathy in adults with either Duchenne or Becker muscular dystrophy [52, 53]. Affecting only one of the multiple molecular processes involved in the pathogenesis of DMD associated cardiomyopathy with PDE 5 inhibition may not have been enough to prevent the development of cardiomyopathy.

The oxidative stress etiology of the development of DMD associated cardiomyopathy has also been explored as a potential modifiable target in pre-clinical studies. NOX-2 inhibition with the compound VAS2870 improved contractility and calcium handling in isolated mdx cardiomyocytes, however NOX inhibition has not yet been explored in an in vivo model [12]. Resveratrol is a polyphenol that activates the NAD + -dependent protein/histone deacetylase SIRT1, which has been found to play a regulatory role in cell survival and stress response. Resveratrol has gained interest as a potential therapeutic in DMD and showed improved skeletal muscle phenotypes in mdx mice along with decreased indices of oxidative stress [54]. Resveratrol has also demonstrated cardioprotective effects in mdx mice, with prevention of cardiac hypertrophy and diastolic dysfunction, improved fractional shortening on echocardiogram, and decreased fibrosis [55, 56]. These improved cardiac measures were accompanied by evidence of improved markers of damaged mitochondrial DNA and decreased ROS levels. Mixed results have been seen when assessing modulators of systemic inflammation. Systolic and diastolic dysfunction as measured by direct invasive measures was prevented in mdx mice treated for a period of time with the transforming growth factor-ß inhibitor, pirfenidone, until 15 months of age. However, pirfenidone did not afford the anticipated improvement in cardiac fibrosis, given its previously demonstrated anti-fibrotic effect in other organs [57]. Conversely, the tumor necrosis factor blocker, Remicade, did prevent the development of fibrosis in both skeletal and cardiac muscle, though was associated with decreased left ventricular ejection fraction by echocardiogram after 32 weeks of treatment [58]. Considering nicorandil targets three separate involved molecular pathways, it may possess greater therapeutic potential and may be superior to other therapeutic candidates.

Our study is not the first to speculate that a more effective therapeutic regimen may be one that acts on multiple pathways implicated in the development of DMD associated cardiomyopathy. One group analyzed the effect of co-administration of ibuprofen and isosorbide dinitrate in mdx mice until ten to eleven months of age. Treatment with this combination of medications had cardioprotective effect with preservation of left ventricular thickness, decreased fibrosis and myocardial inflammation, and improved cardiac responsiveness to dobutamine stress [59]. Treatment with naproxinod, which is a nitric oxide donating derivative of naproxen, also demonstrated cardioprotective effect. Treatment with naproxinod through 9 months of age prevented a decrease in ejection fraction and fractional shortening on echocardiogram and demonstrated a trend in decreased fibrosis on histologic analysis [60]. KATP channel openers have not previously been assessed for effectiveness in pre-clinical or clinical in vivo models of DMD. Given the clinical effectiveness of KATP channel openers in ischemia reperfusion injury and other forms of cardiomyopathy, we are optimistic that the synergistic effect of KATP opening in addition to both anti-inflammatory and nitric oxide donating properties will be a beneficial combination for the treatment of DMD associated cardiomyopathy.

We do recognize that our study does have limitations. This study was performed in young mdx mice subjected to low dose isoproterenol to induce cardiac stress. This subacute injury mouse model simulates the typical clinical course seen in DMD patients who often present with subclinical cardiac fibrosis and borderline or mild decreases in cardiac function. In this subacute injury model, the echocardiographic evidence of cardiac injury is mild, yet a significant increase in myocardial fibrosis accompanied this change in cardiac function associated with isoproterenol injury protocol. The degree of isoproterenol induced fibrosis was more striking, which mimics the clinical course of cardiomyopathy in humans in which fibrosis can be detected by cardiac magnetic resonance imaging prior to the onset of cardiac dysfunction [61]. Further, there was significant variability in degree of isoproterenol induced cardiac injury. All mice, including those with minimal cardiac injury, were included in final analyses, which if anything would underestimate the benefits of nicorandil in our study.

We demonstrated modulation of ROS pathways, though further work needs to be done to better clarify the specific mechanisms by which ROS modulation is occurring. NOX expression showed no notable change in protein expression by immunoblot, which differed from our RT-PCR findings. Similarly, SOD2 showed no notable change in gene expression by RT-PCR, which differed from our immunoblot findings. Interestingly, xanthine oxidase showed no change in expression/activity from untreated vehicle with isoproterenol stress. Rather, nicorandil’s benefits were only seen when given with concomitant isoproterenol stress. This phenomenon has not been seen in other mechanistic studies on nicorandil and would require further investigation to elucidate the mechanism behind these findings. We hypothesize that nicorandil’s modulation of ROS production may not be appreciable until given in conjunction with an ROS producing stressor. If this were the case, nicorandil-mediated decrease in XO mediated superoxide creation would have beneficial physiologic effects with decreased ROS burden. Notably, the isoproterenol induced stressor concluded 5 days prior to tissue collection. While our experimental timing afforded the opportunity to allow for recovery with continued nicorandil treatment, we may have missed the peak inflammatory response to isoproterenol administration and, accordingly, the ability to speculate clearly on mechanisms of reactive oxygen species modulation by nicorandil treatment. Our findings do, however, overall demonstrate that reactive oxygen species production is clearly affected by nicorandil administration, with an overall decrease in reactive oxygen species production.

Conclusions

In conclusion, we report that nicorandil exerts cardioprotective effects in an in vivo mdx mouse model with a prevention of isoproterenol-mediated cardiac dysfunction and fibrosis and anti-oxidant promoting effects seen on many mediators of ROS production. Nicorandil has three mechanisms of action, being a nitric oxide donor, an anti-oxidant, and KATP channel opener. We speculate that the combined action on these separate implicated pathways will afford greater potential as a targeted therapeutic for DMD associated cardiomyopathy. Ongoing studies include a long-term natural history study exploring the cardioprotective effectiveness of nicorandil in the naturally occurring cardiac phenotype in mdx mice before the longer term goal to transition into human clinical trials.

Availability of data and materials

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Abbreviations

DMD:

Duchenne muscular dystrophy

EF:

Ejection fraction

FS:

Fractional shortening

LVEDV:

Left ventricular end diastolic volume

NOX:

NADPH oxidase

iPSC:

Induced pluripotent stem cell

SOD2:

Superoxide dismutase 2

ROS:

Reactive oxygen species

cMRI:

Cardiac magnetic resonance imaging

BMD:

Becker muscular dystrophy

PDE:

Phosphodiesterase

References

  1. Emery AEH. Population frequencies of inherited neuromuscular diseases—a world survey. Neuromuscul Disord. 1991;1:19–29.

    Article  CAS  PubMed  Google Scholar 

  2. Dooley J, Gordon KE, Dodds L, MacSween J. Duchenne muscular dystrophy: a 30-year population-based incidence study. Clin Pediatr (Phila). 2010;49:177–9.

    Article  Google Scholar 

  3. Lapidos KA. The dystrophin glycoprotein complex: signaling strength and integrity for the sarcolemma. Circ Res. 2004;94:1023–31.

    Article  CAS  PubMed  Google Scholar 

  4. Constantin B. Dystrophin complex functions as a scaffold for signalling proteins. Biochim Biophys Acta BBA Biomembr. 2014;1838:635–42.

    Article  CAS  Google Scholar 

  5. Koeks Z, Bladen CL, Salgado D, van Zwet E, Pogoryelova O, McMacken G, et al. Clinical outcomes in duchenne muscular dystrophy: a study of 5345 Patients from the TREAT-NMD DMD global database. J Neuromuscul Dis. 2017;4:293–306.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Kieny P, Chollet S, Delalande P, Le Fort M, Magot A, Pereon Y, et al. Evolution of life expectancy of patients with Duchenne muscular dystrophy at AFM Yolaine de Kepper centre between 1981 and 2011. Ann Phys Rehabil Med. 2013;56:443–54.

    Article  CAS  PubMed  Google Scholar 

  7. Passamano L, Taglia A, Palladino A, Viggiano E, D’Ambrosio P, Scutifero M, et al. Improvement of survival in duchenne muscular dystrophy: retrospective analysis of 835 patients. Acta Myol. 2012;31:121–5.

    PubMed  PubMed Central  Google Scholar 

  8. D’Amario D, Gowran A, Canonico F, Castiglioni E, Rovina D, Santoro R, et al. Dystrophin cardiomyopathies: clinical management, molecular pathogenesis and evolution towards precision medicine. J Clin Med. 2018;7:291.

    Article  PubMed Central  CAS  Google Scholar 

  9. Sapp JL, Bobet J, Howlett SE. Contractile properties of myocardium are altered in dystrophin-deficient mdx mice. J Neurol Sci. 1996;142:17–24.

    Article  CAS  PubMed  Google Scholar 

  10. Fanchaouy M, Polakova E, Jung C, Ogrodnik J, Shirokova N, Niggli E. Pathways of abnormal stress-induced Ca2+ influx into dystrophic mdx cardiomyocytes. Cell Calcium. 2009;46:114–21.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Jung C, Martins AS, Niggli E, Shirokova N. Dystrophic cardiomyopathy: amplification of cellular damage by Ca2+ signalling and reactive oxygen species-generating pathways. Cardiovasc Res. 2008;77:766–73.

    Article  CAS  PubMed  Google Scholar 

  12. Gonzalez DR, Treuer AV, Lamirault G, Mayo V, Cao Y, Dulce RA, et al. NADPH oxidase-2 inhibition restores contractility and intracellular calcium handling and reduces arrhythmogenicity in dystrophic cardiomyopathy. Am J Physiol-Heart Circ Physiol. 2014;307:H710–21.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Khairallah M, Khairallah RJ, Young ME, Allen BG, Gillis MA, Danialou G, et al. Sildenafil and cardiomyocyte-specific cGMP signaling prevent cardiomyopathic changes associated with dystrophin deficiency. Proc Natl Acad Sci. 2008;105:7028–33.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Spurney CF, Guerron AD, Yu Q, Sali A, van der Meulen JH, Hoffman EP, et al. Membrane sealant poloxamer P188 protects against isoproterenol induced cardiomyopathy in dystrophin deficient mice. BMC Cardiovasc Disord. 2011;11:20.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Tinker A, Aziz Q, Thomas A. The role of ATP-sensitive potassium channels in cellular function and protection in the cardiovascular system: ATP-sensitive K + channels. Br J Pharmacol. 2014;171:12–23.

    Article  CAS  PubMed  Google Scholar 

  16. Graciotti L, Becker J, Granata AL, Procopio AD, Tessarollo L, Fulgenzi G. Dystrophin is required for the normal function of the cardio-protective KATP channel in cardiomyocytes. PLoS ONE. 2011;6:27034.

    Article  CAS  Google Scholar 

  17. Yilmaz A, Sechtem U. Cardiac involvement in muscular dystrophy: advances in diagnosis and therapy. Heart. 2012;98:420–9.

    Article  CAS  PubMed  Google Scholar 

  18. D’Amario D, Amodeo A, Adorisio R, Tiziano FD, Leone AM, Perri G, et al. A current approach to heart failure in Duchenne muscular dystrophy. Heart. 2017;103:1770–9.

    Article  PubMed  CAS  Google Scholar 

  19. Nagata K. Nicorandil inhibits oxidative stress-induced apoptosis in cardiac myocytes through activation of mitochondrial ATP-sensitive potassium channels and a nitrate-like effect. J Mol Cell Cardiol. 2003;35:1505–12.

    Article  CAS  PubMed  Google Scholar 

  20. Serizawa K, Yogo K, Aizawa K, Tashiro Y, Ishizuka N. Nicorandil prevents endothelial dysfunction due to antioxidative effects via normalisation of NADPH oxidase and nitric oxide synthase in streptozotocin diabetic rats. Cardiovasc Diabetol. 2011;10:105.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Mano T, Shinohara R, Nagasaka A, Nakagawa H, Uchimura K, Hayashi R, et al. Scavenging effect of nicorandil on free radicals and lipid peroxide in streptozotocin-induced diabetic rats. Metabolism. 2000;49:427–31.

    Article  CAS  PubMed  Google Scholar 

  22. Asensio-López MC, Soler F, Pascual-Figal D, Fernández-Belda F, Lax A. Doxorubicin-induced oxidative stress: the protective effect of nicorandil on HL-1 cardiomyocytes. PLoS ONE. 2017;12:e0172803.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  23. Ahmed LA, El-Maraghy SA. Nicorandil ameliorates mitochondrial dysfunction in doxorubicin-induced heart failure in rats: possible mechanism of cardioprotection. Biochem Pharmacol. 2013;86:1301–10.

    Article  CAS  PubMed  Google Scholar 

  24. Ohno Y, Minatoguchi S, Uno Y, Kariya T, Arai M, Yamashita K, et al. Nicorandil reduces myocardial infarct size by opening the Katp channel in rabbits. Int J Cardiol. 1997;62:181–90.

    Article  CAS  PubMed  Google Scholar 

  25. Mizumura T, Nithipatikom K, Gross GJ. Infarct size-reducing effect of nicorandil is mediated by the ICAT, channel but not by its nitrate-like properties in dogs. 12.

  26. Wu H, Ye M, Yang J, Ding J, Yang J, Dong W, et al. Nicorandil protects the heart from ischemia/reperfusion injury by attenuating endoplasmic reticulum response-induced apoptosis through PI3K/Akt signaling pathway. Cell Physiol Biochem. 2015;35:2320–32.

    Article  CAS  PubMed  Google Scholar 

  27. Zhao X-T, Zhang C-F, Liu Q-J. Meta-analysis of Nicorandil effectiveness on myocardial protection after percutaneous coronary intervention. BMC Cardiovasc Disord. 2019;19:144.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Xu L, Wang L, Li K, Zhang Z, Sun H, Yang X. Nicorandil prior to primary percutaneous coronary intervention improves clinical outcomes in patients with acute myocardial infarction: a meta-analysis of randomized controlled trials. Drug Des Devel Ther. 2019;13:1389–400.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Afzal MZ, Reiter M, Gastonguay C, McGivern JV, Guan X, Ge Z-D, et al. Nicorandil, a nitric oxide donor and ATP-sensitive potassium channel opener, protects against dystrophin-deficient cardiomyopathy. J Cardiovasc Pharmacol Ther. 2016;21:549–62.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  30. Bostick B, Yue Y, Duan D. Gender influences cardiac function in the mdx model of duchenne cardiomyopathy. Muscle Nerve. 2010;42:600–3.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Law ML, Cohen H, Martin AA, Angulski ABB, Metzger JM. Dysregulation of calcium handling in duchenne muscular dystrophy-associated dilated cardiomyopathy: mechanisms and experimental therapeutic strategies. J Clin Med. 2020;9:520.

    Article  CAS  PubMed Central  Google Scholar 

  32. Meyers TA, Heitzman JA, Krebsbach AM, Aufdembrink LM, Hughes R, Bartolomucci A, et al. Acute AT1R blockade prevents isoproterenol-induced injury in mdx hearts. J Mol Cell Cardiol. 2019;128:51–61.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Yue Y. Full-length dystrophin expression in half of the heart cells ameliorates-isoproterenol-induced cardiomyopathy in mdx mice. Hum Mol Genet. 2004;13:1669–75.

    Article  CAS  PubMed  Google Scholar 

  34. Anderson M, Moore D, Larson D. Comparison of isoproterenol and dobutamine in the induction of cardiac hypertrophy and fibrosis. Perfusion. 2008;23:231–5.

    Article  CAS  PubMed  Google Scholar 

  35. Connuck DM, Sleeper LA, Colan SD, Cox GF, Towbin JA, Lowe AM, et al. Characteristics and outcomes of cardiomyopathy in children with Duchenne or Becker muscular dystrophy: a comparative study from the pediatric cardiomyopathy registry. Am Heart J. 2008;155:998–1005.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Quinlan JG, Hahn HS, Wong BL, Lorenz JN, Wenisch AS, Levin LS. Evolution of the mdx mouse cardiomyopathy: physiological and morphological findings. Neuromuscul Disord. 2004;14:491–6.

    Article  PubMed  Google Scholar 

  37. Wang S, Fan Y, Feng X, Sun C, Shi Z, Li T, et al. Nicorandil alleviates myocardial injury and post-infarction cardiac remodeling by inhibiting Mst1. Biochem Biophys Res Commun. 2018;495:292–9.

    Article  CAS  PubMed  Google Scholar 

  38. Hirose M, Takeishi Y, Nakada T, Shimojo H, Kashihara T, Nishio A, et al. Nicorandil prevents Gαq-induced progressive heart failure and ventricular arrhythmias in transgenic mice. PLoS ONE. 2012;7:e52667.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Sonin DL, Wakatsuki T, Routhu KV, Harmann LM, Petersen M, Meyer J, et al. Protease-activated receptor 1 inhibition by SCH79797 attenuates left ventricular remodeling and profibrotic activities of cardiac fibroblasts. J Cardiovasc Pharmacol Ther. 2013;18:460–75.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Cave AC, Brewer AC, Narayanapanicker A, Ray R, Grieve DJ, Walker S, et al. NADPH oxidases in cardiovascular health and disease. Antioxid Redox Signal. 2006;8:691–728.

    Article  CAS  PubMed  Google Scholar 

  41. Pillai VB, Sundaresan NR, Jeevanandam V, Gupta MP. Mitochondrial SIRT3 and heart disease. Cardiovasc Res. 2010;88:250–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Winnik S, Auwerx J, Sinclair DA, Matter CM. Protective effects of sirtuins in cardiovascular diseases: from bench to bedside. Eur Heart J. 2015;36:3404–12.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Sundaresan NR, Samant SA, Pillai VB, Rajamohan SB, Gupta MP. SIRT3 is a stress-responsive deacetylase in cardiomyocytes that protects cells from stress-mediated cell death by deacetylation of Ku70. Mol Cell Biol. 2008;28:6384–401.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Maciel Junior M, Carvalho S, Saenz Suarez PA, Santo Neto H, Marques MJ. Fish oil attenuated dystrophic muscle markers of inflammation via FFA1 and FFA4 in the mdx mouse model of DMD. Anat Rec. 2020;:ar.24563.

  45. Tamura Y, Tanabe K, Kitagawa W, Uchida S, Schreiner GF, Johnson RJ, et al. Nicorandil, a K atp channel opener, alleviates chronic renal injury by targeting podocytes and macrophages. Am J Physiol-Ren Physiol. 2012;303:F339–49.

    Article  CAS  Google Scholar 

  46. Duboc D, Meune C, Lerebours G, Devaux J-Y, Vaksmann G, Bécane H-M. Effect of perindopril on the onset and progression of left ventricular dysfunction in Duchenne muscular dystrophy. J Am Coll Cardiol. 2005;45:855–7.

    Article  CAS  PubMed  Google Scholar 

  47. Duboc D, Meune C, Pierre B, Wahbi K, Eymard B, Toutain A, et al. Perindopril preventive treatment on mortality in Duchenne muscular dystrophy: 10 years’ follow-up. Am Heart J. 2007;154:596–602.

    Article  CAS  PubMed  Google Scholar 

  48. Allen HD, Flanigan KM, Thrush PT, Viollet-Callendret L, Dvorchik I, Yin H, et al. A Randomized, Double-Blind Trial of Lisinopril and Losartan for the Treatment of Cardiomyopathy in Duchenne Muscular Dystrophy. PLOS Curr Muscular Dystrophy. 2013;1.

  49. Dittrich S, Graf E, Trollmann R, Neudorf U, Schara U, Heilmann A, et al. Effect and safety of treatment with ACE-inhibitor Enalapril and β-blocker metoprolol on the onset of left ventricular dysfunction in Duchenne muscular dystrophy - a randomized, double-blind, placebo-controlled trial. Orphanet J Rare Dis. 2019;14:105.

    Article  PubMed  PubMed Central  Google Scholar 

  50. Meyers TA, Townsend D. Cardiac pathophysiology and the future of cardiac therapies in duchenne muscular dystrophy. Int J Mol Sci. 2019;20:4098.

    Article  CAS  PubMed Central  Google Scholar 

  51. Bia BL, Cassidy PJ, Young ME, Rafael JA, Leighton B, Davies KE, et al. Decreased myocardial nNOS, increased iNOS and abnormal ECGs in mouse models of duchenne muscular dystrophy. J Mol Cell Cardiol. 1999;31:1857–62.

    Article  CAS  PubMed  Google Scholar 

  52. Witting N, Kruuse C, Nyhuus B, Prahm KP, Citirak G, Lundgaard SJ, et al. Effect of sildenafil on skeletal and cardiac muscle in Becker muscular dystrophy: Sildenafil in BMD. Ann Neurol. 2014;76:550–7.

    Article  CAS  PubMed  Google Scholar 

  53. Leung DG, Herzka DA, Thompson WR, He B, Bibat G, Tennekoon G, et al. Sildenafil does not improve cardiomyopathy in Duchenne/Becker muscular dystrophy: Sildenafil in DBMD. Ann Neurol. 2014;76:541–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Hori YS, Kuno A, Hosoda R, Tanno M, Miura T, Shimamoto K, et al. Resveratrol ameliorates muscular pathology in the dystrophic mdx mouse, a model for duchenne muscular dystrophy. J Pharmacol Exp Ther. 2011;338:784–94.

    Article  CAS  PubMed  Google Scholar 

  55. Kuno A, Hori YS, Hosoda R, Tanno M, Miura T, Shimamoto K, et al. Resveratrol improves cardiomyopathy in dystrophin-deficient mice through SIRT1 protein-mediated modulation of p300 protein. J Biol Chem. 2013;288:5963–72.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Kuno A, Hosoda R, Sebori R, Hayashi T, Sakuragi H, Tanabe M, et al. Resveratrol ameliorates mitophagy disturbance and improves cardiac pathophysiology of dystrophin-deficient mdx mice. Sci Rep. 2018;8:15555.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  57. Van Erp C, Irwin NG, Hoey AJ. Long-term administration of pirfenidone improves cardiac function inmdx mice. Muscle Nerve. 2006;34:327–34.

    Article  PubMed  CAS  Google Scholar 

  58. Ermolova NV, Martinez L, Vetrone SA, Jordan MC, Roos KP, Sweeney HL, et al. Long-term administration of the TNF blocking drug Remicade (cV1q) to mdx mice reduces skeletal and cardiac muscle fibrosis, but negatively impacts cardiac function. Neuromuscul Disord. 2014;24:583–95.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Sciorati C, Staszewsky L, Zambelli V, Russo I, Salio M, Novelli D, et al. Ibuprofen plus isosorbide dinitrate treatment in the mdx mice ameliorates dystrophic heart structure. Pharmacol Res. 2013;73:35–43.

    Article  CAS  PubMed  Google Scholar 

  60. Uaesoontrachoon K, Quinn JL, Tatem KS, Van Der Meulen JH, Yu Q, Phadke A, et al. Long-term treatment with naproxcinod significantly improves skeletal and cardiac disease phenotype in the mdx mouse model of dystrophy. Hum Mol Genet. 2014;23:3239–49.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Silva MC, Meira ZMA, Gurgel Giannetti J, da Silva MM, Oliveira Campos AF, de Melo BM, et al. Myocardial delayed enhancement by magnetic resonance imaging in patients with muscular dystrophy. J Am Coll Cardiol. 2007;49:1874–9.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

Sincere thanks to Leanne Harmann, BA RDCS, RDMS, RVT for her guidance and instruction in performing and interpreting mouse echocardiograms.

Funding

This work was supported by the National Institutes of Health (NIH R01 HL134932) as well as a contribution from the Herma Heart Institute (Children’s Wisconsin, Milwaukee, WI).

Author information

Authors and Affiliations

  1. Medical College of Wisconsin, 8701 W Watertown Plank Rd, Milwaukee, WI, 53226, USA

    Rachel T. Sullivan, Ngoc T. Lam, Margaret Haberman, Margaret J. Beatka, Muhammad Z. Afzal, Michael W. Lawlor & Jennifer L. Strande

Authors
  1. Rachel T. Sullivan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ngoc T. Lam
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Margaret Haberman
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Margaret J. Beatka
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Muhammad Z. Afzal
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Michael W. Lawlor
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Jennifer L. Strande
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

R.T.S. wrote the main manuscript text, performed and analyzed echocardiograms, and performed xanthine oxidase assay. N.T.L., M.H., and M.Z.A. carried out the mouse treatment protocols. R.T.S., N.T.L., and M.J.B. performed Western blot analysis. M.Z.A. performed PCR analysis. R.T.S. and M.H. performed histologic evaluation of cardiac tissue. M.W.L. provided consultation regarding histologic analysis and western blot analyses. J.L.S. had a primary role in project development and was involved and oversight of all experiments and data analysis. All authors reviewed the manuscript. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Rachel T. Sullivan.

Ethics declarations

Ethics approval and consent to participate

All applicable. International, national, and/or institutional guidelines for care and use of laboratory animals were followed. All animal experiments were performed at the Medical College of Wisconsin and were approved by the institutional animal care and use committee (procedure protocol AUA00003547). This study was carried out in compliance with the ARRIVE guidelines. No informed consent was required as no human subject research was conducted.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Additional file 1

. This supplemental figure shows the uncropped original blots for vinculin loading control and superoxide dismutase 2 (SOD2). 

Additional file 2

. This supplemental figure shows the uncropped original blots for vinculin loading control and sirtuin 3. The sirtuin 3 band of interest is identified by the red arrow. 

Additional file 3

.This supplemental figure shows the uncropped original blots for vinculin loading control, NFkB, and TNFα. These were assessed on different regions of the same membrane. The NFkB and TNFα bands of interest are identified by the red arrows.

Additional file 4

.This supplemental figure shows the uncropped original blots for vinculin loading control and NADPH oxidase 4 (NOX4).

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sullivan, R.T., Lam, N.T., Haberman, M. et al. Cardioprotective effect of nicorandil on isoproterenol induced cardiomyopathy in the Mdx mouse model. BMC Cardiovasc Disord 21, 302 (2021). https://doi.org/10.1186/s12872-021-02112-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12872-021-02112-4

Keywords

BMC Cardiovascular Disorders

ISSN: 1471-2261

Contact us